Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$1.96 - $3.32 $2.28 Million - $3.86 Million
-1,163,945 Reduced 37.02%
1,979,828 $4.08 Million
Q2 2022

Aug 12, 2022

BUY
$2.27 - $4.86 $7.14 Million - $15.3 Million
3,143,773 New
3,143,773 $8.71 Million
Q4 2021

Feb 14, 2022

SELL
$5.37 - $7.07 $6.24 Million - $8.21 Million
-1,161,466 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.54 - $7.51 $1.73 Million - $2.34 Million
311,466 Added 36.64%
1,161,466 $7.18 Million
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $1.4 Million - $2.05 Million
-180,004 Reduced 17.48%
850,000 $7.23 Million
Q1 2021

May 14, 2021

BUY
$5.12 - $8.48 $4.15 Million - $6.87 Million
810,664 Added 369.59%
1,030,004 $8.15 Million
Q4 2020

Feb 12, 2021

SELL
$3.16 - $7.03 $437,110 - $972,431
-138,326 Reduced 38.67%
219,340 $1.28 Million
Q3 2020

Nov 13, 2020

BUY
$3.26 - $4.73 $1.17 Million - $1.69 Million
357,666 New
357,666 $1.21 Million
Q2 2020

Aug 13, 2020

SELL
$1.58 - $4.63 $4.74 Million - $13.9 Million
-3,000,000 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$1.44 - $3.02 $1.45 Million - $3.05 Million
-1,010,155 Reduced 25.19%
3,000,000 $4.74 Million
Q4 2019

Feb 13, 2020

BUY
$2.25 - $3.07 $8.85 Million - $12.1 Million
3,931,655 Added 5008.48%
4,010,155 $11 Million
Q3 2019

Nov 13, 2019

SELL
$2.67 - $3.65 $1.7 Million - $2.33 Million
-637,254 Reduced 89.03%
78,500 $231,000
Q2 2019

Aug 13, 2019

BUY
$2.6 - $4.21 $546,046 - $884,175
210,018 Added 41.53%
715,754 $2.05 Million
Q1 2019

May 14, 2019

SELL
$3.05 - $4.34 $635,446 - $904,208
-208,343 Reduced 29.18%
505,736 $2.12 Million
Q4 2018

Feb 13, 2019

BUY
$2.82 - $4.67 $2.01 Million - $3.33 Million
714,079 New
714,079 $2.22 Million

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.